INTRODUCTION: There is evidence that TGF-beta 1 plays a role as a tumor suppressor in early disease and has pro-oncogenic effects in advanced tumor stage. The aim of the study was to correlate TGF-beta 1 in plasma and tissue to clinical and pathological parameters in patients with various stages of disease progression. METHODS: One hundred sixty-nine patients who underwent surgery for a colorectal carcinoma were prospectively included. Blood samples, tumor free mucosa and tumor biopsies were assayed. RESULTS: TGF-beta 1 protein expression in tumors increased with increasing T-stage regardless of whether patients with metastatic disease were included or not (P = 0.0006). Patients with metastatic disease showed elevated TGF-beta 1 protein expression in both tumor tissue (P = 0.004) and plasma (P = 0.001) compared to those without metastatic disease. TGF-beta 1 protein expression was higher in the colon compared with the rectum in both tumor tissue and tumor-free bowel (P = 0.03), regardless of whether patients with metastatic disease were included or not. This difference was mainly attributable to a higher TGF-beta 1 protein expression in non-metastatic patients with lymph node positivity (P = 0.005). CONCLUSIONS: Higher TGF-beta 1 protein expression is associated with increasing T-stage and metastatic disease, indicating that TGF-beta 1 is of importance in tumor progression. The localization of the tumor seems to influence the TGF-beta 1 protein expression in patients with tumor cell-positive lymph nodes. (Copyright) 2008 Wiley-Liss, Inc.
INTRODUCTION: There is evidence that TGF-beta 1 plays a role as a tumor suppressor in early disease and has pro-oncogenic effects in advanced tumor stage. The aim of the study was to correlate TGF-beta 1 in plasma and tissue to clinical and pathological parameters in patients with various stages of disease progression. METHODS: One hundred sixty-nine patients who underwent surgery for a colorectal carcinoma were prospectively included. Blood samples, tumor free mucosa and tumor biopsies were assayed. RESULTS:TGF-beta 1 protein expression in tumors increased with increasing T-stage regardless of whether patients with metastatic disease were included or not (P = 0.0006). Patients with metastatic disease showed elevated TGF-beta 1 protein expression in both tumor tissue (P = 0.004) and plasma (P = 0.001) compared to those without metastatic disease. TGF-beta 1 protein expression was higher in the colon compared with the rectum in both tumor tissue and tumor-free bowel (P = 0.03), regardless of whether patients with metastatic disease were included or not. This difference was mainly attributable to a higher TGF-beta 1 protein expression in non-metastatic patients with lymph node positivity (P = 0.005). CONCLUSIONS: Higher TGF-beta 1 protein expression is associated with increasing T-stage and metastatic disease, indicating that TGF-beta 1 is of importance in tumor progression. The localization of the tumor seems to influence the TGF-beta 1 protein expression in patients with tumor cell-positive lymph nodes. (Copyright) 2008 Wiley-Liss, Inc.
Authors: Daniel R Principe; Jennifer A Doll; Jessica Bauer; Barbara Jung; Hidayatullah G Munshi; Laurent Bartholin; Boris Pasche; Chung Lee; Paul J Grippo Journal: J Natl Cancer Inst Date: 2014-02 Impact factor: 13.506
Authors: Izabela Winkler; Barbara Wilczynska; Agnieszka Bojarska-Junak; Marek Gogacz; Aneta Adamiak; Krzysztof Postawski; Dorota Darmochwal-Kolarz; Tomasz Rechberger; Jacek Tabarkiewicz Journal: J Ovarian Res Date: 2015-06-17 Impact factor: 4.234
Authors: Caitlyn W Barrett; Kshipra Singh; Amy K Motley; Mary K Lintel; Elena Matafonova; Amber M Bradley; Wei Ning; Shenika V Poindexter; Bobak Parang; Vishruth K Reddy; Rupesh Chaturvedi; Barbara M Fingleton; Mary K Washington; Keith T Wilson; Sean S Davies; Kristina E Hill; Raymond F Burk; Christopher S Williams Journal: PLoS One Date: 2013-07-04 Impact factor: 3.240